About this Research Topic
The indications for ECMO have been widely expanded recently due to the improvement of technology. According to our data analyzed in autopsy cases, 97% patients were noted to have bleeding in at least one organ system and 57% patients were found to have thrombosis (Otterness, C, Soundar, E, Eldin, K, Teruya, J.). This highlights the importance and urgency of gaining more understanding about the pathophysiology of bleeding and thrombosis in ECMO since it is multifactorial, results in increased mortality, and is poorly understood.
We may discuss the following in the setting of ECMO:
• Acquired von Willebrand syndrome
• Coagulation and inflammation in ECMO and potential novel anticoagulant drug targets
• Hemolysis and von Willebrand factor
• Definitionfor bleeding and clotting
• Neonatal ECMO
• Anticoagulant monitoring tests
We may discuss the following in the setting of ECMO:
• Acquired von Willebrand syndrome
• Coagulation and inflammation in ECMO and potential novel anticoagulant drug targets
• Hemolysis and von Willebrand factor
• Definitionfor bleeding and clotting
• Neonatal ECMO
• Anticoagulant monitoring tests
Keywords: ECMO, VAD, bleeding, thrombosis, anticoagulation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
